Adrián Alegre Amor

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 327 citations

Medicine, Hematology, Oncology +14

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero et al. · Blood · 2019 · 62 citations

Medicine, Hematology, Oncology +11

Microtransferrinuria is a more sensitive indicator of early glomerular damage in diabetes than microalbuminuria.

Alfred Bernard, Adrián Alegre Amor, J. Goemaere-Vanneste et al. · PubMed · 1988 · 48 citations

Medicine, Internal Medicine, Nephrology +13

Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab

María‐Victoria Mateos, Albert Oriol, Alessandra Larocca et al. · Blood · 2019 · 12 citations

Medicine, Oncology, Pharmacotherapy +12

Safety and Preliminary Efficacy Results from a Phase Ib/II Study of Cobimetinib As a Single Agent and in Combination with Venetoclax with or without Atezolizumab in Patients with Relapsed/Refractory Multiple Myeloma

Fredrik Schjesvold, Vincent Ribrag, Paula Rodríguez‐Otero et al. · Blood · 2020 · 11 citations

Medicine, Oncology, Pharmacology +11